Clinical Trial News and Research

RSS

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment.

13 May 2010

AlphaRx continues to develop Indaflex for the Chinese market

AlphaRx, Inc., has been advised by Cypress Biosciences, its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding to the termination of all Indaflex activity in the U.S.A., AlphaRx continues to develop Indaflex for the Chinese market.

13 May 2010

Amarin reports cash balance of $44 million for first-quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported selected financial results for the fiscal quarter ended March 31, 2010 and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

12 May 2010

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

12 May 2010

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Study confirms Resveratrol's impact on cognitive processes of the brain

The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community. And as evidence comes to light of the continuing beneficial effects of this compound, a further study by the University of Northumbria in the UK has confirmed what many scientists already believe to be the case - that Resveratrol could have a significant impact on the cognitive processes of the human brain.

12 May 2010

Adult patients with sickle cell disease may develop cognitive problems: Study

Sickle cell disease may affect brain function in adults who have few or mild complications of the inherited blood disease, according to results of the first study to examine cognitive functioning in adults with sickle cell disease.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.

12 May 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer." Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

11 May 2010

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

Clinical Trial News and Research

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

AlphaRx continues to develop Indaflex for the Chinese market

Amarin reports cash balance of $44 million for first-quarter 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Study confirms Resveratrol's impact on cognitive processes of the brain

Adult patients with sickle cell disease may develop cognitive problems: Study

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

China Pharma first-quarter revenue up 16% to $15.1 million

MediciNova announces $15 million senior secured term loan with Oxford Finance

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer